Taysha Gene Therapies, Inc. TSHA Increase Decrease In Accrued Expense And Other Liabilities
Increase Decrease In Accrued Expense And Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept tsha:IncreaseDecreaseInAccruedExpenseAndOtherLiabilities.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s increase decrease in accrued expense and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s increase decrease in accrued expense and other liabilities?
- Taysha Gene Therapies, Inc. (TSHA) reported increase decrease in accrued expense and other liabilities of -$5.15M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s increase decrease in accrued expense and other liabilities changed year-over-year?
- Taysha Gene Therapies, Inc.'s increase decrease in accrued expense and other liabilities decreased by 142.3% year-over-year, from -$2.13M to -$5.15M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s increase decrease in accrued expense and other liabilities?
- Over 2 years (2022 to 2025), Taysha Gene Therapies, Inc.'s increase decrease in accrued expense and other liabilities has grown at a -17.9% compound annual growth rate (CAGR), from -$9.32M to $6.29M.
- What does increase decrease in accrued expense and other liabilities mean?
- This metric tracks the net change in short-term obligations owed to vendors, employees, or service providers that have not yet been settled in cash. An increase indicates that the company is deferring cash outflows, while a decrease reflects the settlement of these liabilities. It serves as a key indicator of short-term working capital management.